Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
- Market Exclusivity for Lunesta Extended 6 Months in the US: DSP
July 30, 2012
- Celgene Initiates PII Trial in Japan for Revlimid in Treatment-Naïve Patients with Multiple Myeloma
July 30, 2012
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
- Serum Ca Levels Show No Increase in Coadministration of Forteo, Activated Vitamin D3: Eli Lilly Japan
July 27, 2012
- Keizai Doyukai Chairman Hasegawa Instructs Takeda to Create Countermeasures for Risk of Violence in Emerging Countries
July 27, 2012
- Tarceva Shows No Significant Difference in PIII Study, Indication for Hepatoma Difficult: Astellas
July 26, 2012
- Kyowa Hakko Bio’s Subsidiary Completes Drug Substance Production Facility Conforming to Japan, US, Europe GMPs
July 26, 2012
- Takeda Receives Positive Opinion from CHMP on Adcetris
July 26, 2012
- Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
- Sandoz Launches Generic Claritin
July 26, 2012
- MTPC Launches Low-dose Anxiolytic Depas on July 24
July 26, 2012
- MSD Changes Name of Aroglycem to Diazoxide to Prevent Medication Errors
July 25, 2012
- MSD to File NDA for Odanacatib in Japan in First Half of 2013
July 25, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…